Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.25%||162.64||0.7%||$1229.36m|
|MRK||Merck & Co., Inc.||0.18%||77.61||0.7%||$782.74m|
|BMY||Bristol-Myers Squibb Co.||0.44%||65.75||1.0%||$703.61m|
|LLY||Eli Lilly & Co.||0.25%||189.73||1.1%||$539.14m|
|RPRX||Royalty Pharma Plc||-0.24%||41.77||0.2%||$91.76m|
|NVO||Novo Nordisk A/S||0.75%||72.71||0.1%||$62.90m|
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.